ClinVar Miner

Submissions for variant NM_001127222.2(CACNA1A):c.6610G>A (p.Asp2204Asn)

gnomAD frequency: 0.00002  dbSNP: rs747673128
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000521439 SCV000618859 uncertain significance not provided 2024-07-17 criteria provided, single submitter clinical testing Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge
Labcorp Genetics (formerly Invitae), Labcorp RCV001318420 SCV001509119 uncertain significance Episodic ataxia type 2; Developmental and epileptic encephalopathy, 42 2023-12-02 criteria provided, single submitter clinical testing This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 2205 of the CACNA1A protein (p.Asp2205Asn). This variant is present in population databases (rs747673128, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with CACNA1A-related conditions. ClinVar contains an entry for this variant (Variation ID: 450295). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on CACNA1A protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV003258847 SCV003978137 uncertain significance Inborn genetic diseases 2023-05-15 criteria provided, single submitter clinical testing The c.6613G>A (p.D2205N) alteration is located in exon 46 (coding exon 46) of the CACNA1A gene. This alteration results from a G to A substitution at nucleotide position 6613, causing the aspartic acid (D) at amino acid position 2205 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.